Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
about
Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS blockTherapeutic approaches for celiac diseaseCellular functions of tissue transglutaminaseRole of transglutaminase 2 in celiac disease pathogenesisActivation and inhibition of transglutaminase 2 in miceCompensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor TreatmentNovel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomasExtracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury.Parallels between pathogens and gluten peptides in celiac sprueTransglutaminase regulation of cell function.Dihydroisoxazole inhibitors of Anopheles gambiae seminal transglutaminase AgTG3Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration?Novel therapies for coeliac diseaseReview article: coeliac disease, new approaches to therapy.Update on celiac disease - etiology, differential diagnosis, drug targets, and management advances.Thioredoxin is involved in endothelial cell extracellular transglutaminase 2 activation mediated by celiac disease patient IgA.Two isoforms of tissue transglutaminase mediate opposing cellular fates.Characterization of transglutaminase type II role in dendritic cell differentiation and function.Transglutaminase 2 inhibitors and their therapeutic role in disease states.Molecular mechanisms of the adaptive, innate and regulatory immune responses in the intestinal mucosa of celiac disease patients.Future therapeutic options for celiac disease.Tissue transglutaminase: a new target to reverse cancer drug resistanceTissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity.Transglutaminase activation in neurodegenerative diseases.Transglutaminase 2 as a novel activator of LRP6/β-catenin signaling.Investigational therapies for celiac disease.Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation.Potential of transglutaminase 2 as a therapeutic target.Pharmacotherapy and management strategies for coeliac disease.Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management.Recent advances in the development of tissue transglutaminase (TG2) inhibitors.Celiac disease: the search for adjunctive or alternative therapies.Transglutaminase as a therapeutic target for celiac disease.Celiac disease 2015 update: new therapies.Transglutaminase inhibitors: a patent review.Physiopathology and Management of Gluten-Induced Celiac Disease.Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
P2860
Q26824549-4A3E0B21-AAE2-4057-8FEF-712233EF8FAEQ26825413-367006E4-1438-4DFF-A8CF-C7E46334A650Q28260600-E7A9FF7B-5F8B-460D-B323-DB17F2ADE1C4Q28262529-D5BB1897-1645-4412-97A4-838D8B1BC60EQ28480486-BC039046-4F41-40C0-B907-511FB7050CE0Q28550149-9409B991-2664-4BA4-A2BF-2FF8853B7FCBQ30542102-DD15B552-02ED-4C37-B37F-150835E95C9BQ33325485-AE244911-B12B-42F9-82E4-F83A07BA00C1Q33329537-67DB48AC-59ED-4869-9B8F-ED61E6F31C12Q33707936-C434E6FE-B392-45D4-A3F7-D6D52EBBA9DCQ33959419-5D5CB394-4153-4342-AAD4-540B51365411Q34031863-06E41642-4705-4DAE-824A-D961B6660AF4Q34170574-6208F3F6-1ACE-47A8-A861-8176BE0EAE14Q34253519-B4FB4347-026F-404E-BF5B-4791CDB65D5FQ34635029-534ADD7F-F6EC-4DA3-A8FB-8218A1619270Q35018831-6381EDF6-2470-4CEA-9EC3-3B7A62A3F47CQ35157424-7ACD62F6-1506-4B2D-BF6C-17486F210A5CQ35534802-C0FB2BF2-1D56-4686-BA43-DA01BDE38D71Q35989247-A0E180E6-9B7E-4CDE-9150-409202A0340DQ36252174-9451F35C-9733-4F25-8669-0691F04091A5Q36304110-39C519E1-F315-4582-8EBD-FBFA85DC2376Q36503511-97748FE7-443E-4418-B8F7-DD23AEEF450BQ36916874-1BF5147B-B549-476A-9217-C4799DB6EC8AQ37057882-022CF18E-AD35-4EFF-A139-B304A03A6EA3Q37257253-E8D00AC9-C4E1-479F-82B9-D599FF17EA2BQ37352964-560045DB-FD5F-4BF6-8B85-C519F4150BA8Q37434321-CF38C3C9-36C1-4DA1-914A-166A807966F9Q37638684-D99CF7BD-2B5A-405A-8D90-0A24BE54CC27Q37685405-DF6AFF86-BE2C-485F-ADAD-38B402E687C2Q37776508-746FEAB8-B1A4-4B67-B299-526EFA7D26D5Q37896092-10CA19F0-FF59-42F0-AF4F-CE13233AD522Q37965669-694FFAE9-1829-4AB5-8226-8ED66675F115Q37967368-B87DE969-ECB3-4BE6-8171-1238E9867D41Q38184586-7094EFB8-5B4D-441B-A336-56C01A48CC9DQ38269678-B85E256E-138F-4826-8A1D-9A714301AB2FQ38416745-5DB3D9C4-06B2-41A5-984C-7C34C43B35C5Q38631307-47066FBA-E463-4D52-8790-6857B831C77CQ39111493-8D4B1ACE-004C-4CD8-A526-BD6E3D39E2E7Q39162858-AD84CCC2-62B7-482D-B80C-BBC0ED4B1DF7Q39268578-10001C7C-5DF4-4F7B-8D98-E9714406CC64
P2860
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Chemistry and biology of dihyd ...... s of human transglutaminase 2.
@en
type
label
Chemistry and biology of dihyd ...... s of human transglutaminase 2.
@en
prefLabel
Chemistry and biology of dihyd ...... s of human transglutaminase 2.
@en
P2093
P1476
Chemistry and biology of dihyd ...... rs of human transglutaminase 2
@en
P2093
Chaitan Khosla
Justin L Piper
Keith M Rich
Matthew Siegel
Pavel Strnad
P304
P356
10.1016/J.CHEMBIOL.2005.02.007
P577
2005-04-01T00:00:00Z